Welcome to our dedicated page for HNGR news (Ticker: HNGR), a resource for investors and traders seeking the latest updates and insights on HNGR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HNGR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HNGR's position in the market.
Hanger, Inc. (NYSE: HNGR) has completed its acquisition by Patient Square Capital, an all-cash transaction valued at $18.75 per share for Hanger stockholders. The deal was approved at a Special Meeting on September 30, 2022. Following the acquisition, Hanger will transition to a private entity, allowing for greater investment flexibility in future growth initiatives. CEO Vinit Asar emphasizes the commitment to patient care and growth under Patient Square's leadership.
Hanger, Inc. (NYSE: HNGR) has received stockholder approval for its acquisition by Patient Square Capital, a healthcare investment firm. Under the merger agreement dated July 21, 2022, shareholders will receive $18.75 in cash per share of common stock. The acquisition marks Hanger's transition to a privately held company, with trading on the NYSE expected to cease following the transaction's completion. CEO Vinit Asar expressed gratitude to shareholders and optimism regarding growth and enhanced service capabilities post-acquisition.
Hanger, Inc. (NYSE: HNGR) released its financial results for Q2 2022, reporting net revenues of $312.0 million, an 11.1% increase from Q2 2021. Net income stood at $10.1 million with adjusted EBITDA rising to $35.5 million, a 14.5% growth. The Patient Care segment grew 12.2%, supported by acquisitions. However, payor disallowances increased to 4.4% of gross charges, impacting revenue. In a significant move, Hanger announced a merger with Patient Square Capital, with each share valued at $18.75, leading to its delisting from NYSE.
Hanger, Inc. (NYSE: HNGR) has announced a definitive agreement for its acquisition by Patient Square Capital at a cash price of
Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic services, will report its financial results for the second quarter and six months ending June 30, 2022, after the market closes on August 8, 2022. A conference call is scheduled for August 9, 2022, at 8:30 a.m. ET to discuss these results. Investors can participate by dialing (844) 200-6205 and referencing access code 020458. The earnings release and a replay of the call will be available on the company's Investor Relations website.
Hanger, Inc. (NYSE: HNGR), a leader in orthotic and prosthetic patient care, announced management participation at the Jefferies Healthcare Conference from June 8-10, 2022. A key presentation is scheduled for June 9 at 10:30 a.m. Eastern time, with a live webcast available on the company's investor relations website. Hanger operates approximately 875 Hanger Clinic locations across the U.S., providing comprehensive O&P services. Recognized by Forbes as one of America’s Best Employers for 2022, Hanger aims to empower human potential through superior patient care and innovation.
Hanger, Inc. (NYSE: HNGR) reported first-quarter 2022 net revenues of $261.3 million, up 10.0% from $237.5 million in Q1 2021. However, the company posted a net loss of $8.0 million, compared to a loss of $3.3 million a year earlier. Same clinic revenue grew 6.9%, driven by improved patient volumes. Adjusted EBITDA decreased to $8.9 million from $13.5 million. The company reaffirmed its guidance for 2022, anticipating net revenue between $1.190 billion and $1.220 billion.
Hanger, Inc. (NYSE: HNGR) will report its first quarter financial results on
Hanger, Inc. (NYSE: HNGR) reported its Q4 and full-year 2021 financial results, highlighting net revenues of $312.4 million, up 12.6% from Q4 2020. However, net income decreased to $14.0 million from $16.1 million year-over-year. Adjusted EBITDA rose to $37.2 million, a 4.9% increase. For the full year, net revenues reached $1.120 billion, an 11.9% growth. Despite challenges from COVID-19, growth was driven by increased patient volumes and acquisitions, positioning Hanger well for 2022 with projected revenues between $1.190 billion and $1.220 billion.
FAQ
What is the market cap of HNGR (HNGR)?
